MedTrace Logo

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

NCT01164696 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2010-08-24

No results posted yet for this study

Summary

The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.

Conditions

Interventions

DRUG

[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Zevalin was administered according to the directives in the approved package leaflet.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Belgium

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01164696 on ClinicalTrials.gov